Genetic Alterations of the p14ARF-hdm2-p53 Regulatory Pathway in Breast Carcinoma
10.1023/a:1010686518990
Crossref journal-article
Springer Science and Business Media LLC
Breast Cancer Research and Treatment (297)
Bibliography

Ho, G. H., Calvano, J. E., Bisogna, M., Abouezzi, Z., Borgen, P. I., Cordón-Cardó, C., & Zee, K. J. V. (2001). Genetic Alterations of the p14ARF-hdm2-p53 Regulatory Pathway in Breast Carcinoma. Breast Cancer Research and Treatment, 65(3), 225–232.

Authors 7
  1. Gay Hui Ho (first)
  2. Jacqueline E. Calvano (additional)
  3. Maria Bisogna (additional)
  4. Ziad Abouezzi (additional)
  5. Patrick I. Borgen (additional)
  6. Carlos Cordón-Cardó (additional)
  7. Kimberly J. Van Zee (additional)
References 43 Referenced 19
  1. Runnebaum IB, Nagarajan M, Bowman M, Soto D, Sukumar S: Mutations in p53 as potential molecular markers for human breast cancer. Proc Natl Acad Sci USA 88: 10657-10661, 1991 (10.1073/pnas.88.23.10657) / Proc Natl Acad Sci USA by IB Runnebaum (1991)
  2. Osborne RJ, Merlo GR, Mitsudomi T, Venesio T, Liscia DS, Cappa APM, Chiba I, Takahashi T, Nau NM, Callahan R, Minna JD: Mutations in the p53 gene in primary human breast cancers. Cancer Res 51: 6194-6198, 1991 / Cancer Res by RJ Osborne (1991)
  3. Elledge RM, Fuqua SAW, Clark GM, Pujol P, Allred C, McGuire WL: Prognostic significance of p53 gene alterations in node-negative breast cancer. Breast Cancer Res Treat 26: 225-235, 1993 (10.1007/BF00665800) / Breast Cancer Res Treat by RM Elledge (1993)
  4. Bergh J, Norberg T, Sjögren S, Lindgren A, Holmberg L: Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1: 1029-1034, 1995 (10.1038/nm1095-1029) / Nat Med by J Bergh (1995)
  5. Kovach JS, Hartmann A, Blaszyk H, Cunningham J, Schaid D, Sommer SS: Mutation detected by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci USA 93: 1093-1096, 1996 (10.1073/pnas.93.3.1093) / Proc Natl Acad Sci USA by JS Kovach (1996)
  6. Cuny M, Kramar A, Courgal F, Johannsdottir V, Iacopetta B, Fontaine H, Grenier J, Culine S, Theillet C: Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cancer Res 60: 1077-1083, 2000 / Cancer Res by M Cuny (2000)
  7. Momand J, Zambetti GP, Olson DC, George D, Levine AJ: The mdm-2 oncogene product forms a complex with the p53 prote in and inhibits p53-mediated transactivation. Cell 69: 1237-1245, 1992 (10.1016/0092-8674(92)90644-R) / Cell by J Momand (1992)
  8. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B.: Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature 362: 857-860, 1993 (10.1038/362857a0) / Nature by JD Oliner (1993)
  9. Levine AJ: The p53 protein and its interactions with the oncogene products of the small DNA tumor viruses. Virology 177: 419-426, 1990 (10.1016/0042-6822(90)90505-L) / Virology by AJ Levine (1990)
  10. Wu X, Bayle H, Olson D, Levine AJ: The p53-mdm-2 autoregulatory feedback loop. Genes Dev 7: 1126-1132, 1993 (10.1101/gad.7.7a.1126) / Genes Dev by X Wu (1993)
  11. Haupt Y, Maya R, Kazaz A, Oren M: Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299, 1997 (10.1038/387296a0) / Nature by Y Haupt (1997)
  12. Kubbutat MH, Jones SN, Vousden KH: Regulation of p53 stability by Mdm2. Nature 387: 299-303, 1997 (10.1038/387299a0) / Nature by MH Kubbutat (1997)
  13. Leach FS, Tokino P, Meltzer M, Burrell JD, Oliner S, Smith DE, Hill D, Sidransky KW, Kinzler K, Vogelstein B: p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 53: 2231-2234, 1993 / Cancer Res by FS Leach (1993)
  14. Fakharzadeh SS, Trusko SP, George DL: Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 10: 1565-1569, 1991 (10.1002/j.1460-2075.1991.tb07676.x) / EMBO J by SS Fakharzadeh (1991)
  15. Finlay C: The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 13: 301-306, 1993 / Mol Cell Biol by C Finlay (1993)
  16. Courjal F, Rodriguez C, Louason G, Speiser P, Katsaros D, Tanner MM, Zeillinger R, Theillet C: DNA amplifications at 20q13 andMDM2 define distinct subsets of evolved breast and ovarian tumours. Br J Cancer 74: 1984-1989, 1996 (10.1038/bjc.1996.664) / Br J Cancer by F Courjal (1996)
  17. McCann AH, Kirley A, Carney DN, Corbally N, Magee HM, Keating G, Dervan PA: Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. Br J Cancer 71: 981-985, 1995 (10.1038/bjc.1995.189) / Br J Cancer by AH McCann (1995)
  18. Marchetti A, Buttita F, Girlando S, Dalla Palma P, Pellegrini S, Fina P, Doglioni C, Bevilacqua G, Barbareschi M: mdm2 gene alterations and mdm2 protein expression in breast carcinomas. J Pathol 175: 31-38, 1995 (10.1002/path.1711750106) / J Pathol by A Marchetti (1995)
  19. Pomerantz J, Schreiber-Agus N, Liégeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee H-W, Cordón-Cardó C, DePinho RA: The INK4a tumor suppressor gene product, p19ARF, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92: 713-723, 1998 (10.1016/S0092-8674(00)81400-2) / Cell by J Pomerantz (1998)
  20. Zhang Y, Xiong Y, Yarbrough WG: ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725-734, 1998 (10.1016/S0092-8674(00)81401-4) / Cell by Y Zhang (1998)
  21. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH, Peters G: The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J 17: 5001-5014, 1998 (10.1093/emboj/17.17.5001) / EMBO J by FJ Stott (1998)
  22. Quelle DE, Zindy F, Ashmun RA, Sherr CJ: Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993-1000, 1995 (10.1016/0092-8674(95)90214-7) / Cell by DE Quelle (1995)
  23. Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ, Sidransky D: A novel p16INK4A transcript. Cancer Res 55: 2995-2997, 1995 / Cancer Res by L Mao (1995)
  24. Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, Peters G, Kamb A: Complex structure and regulation of the P16 (MST1) locus. Cancer Res 55: 2988-2994, 1995 / Cancer Res by S Stone (1995)
  25. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G, Sherr CJ: Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91: 649-659, 1997 (10.1016/S0092-8674(00)80452-3) / Cell by T Kamijo (1997)
  26. Quelle DE, Cheng M, Ashmun RA, Sherr CJ: Cancerassociated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF. Proc Natl Acad Sci USA 94: 669-673, 1997 (10.1073/pnas.94.2.669) / Proc Natl Acad Sci USA by DE Quelle (1997)
  27. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual, 2nd edn, Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989 / Molecular Cloning: A Laboratory Manual by J Sambrook (1989)
  28. Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, Magrath IT, Knowles DM, Dalla-Favera R: p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 88: 5413-5417, 1991 (10.1073/pnas.88.12.5413) / Proc Natl Acad Sci USA by G Gaidano (1991)
  29. Anelli A, Anelli TFM, Youngson B, Rosen PP, Borgen PI: Mutations in the p53 gene in male breast cancer. Cancer 75: 2233-2238, 1995 (10.1002/1097-0142(19950501)75:9<2233::AID-CNCR2820750907>3.0.CO;2-S) / Cancer by A Anelli (1995)
  30. Frye RA, Benz CC, Liu E: Detection of amplified oncogenes by differential polymerase chain reaction. Oncogene 4: 1153-1157, 1989 / Oncogene by RA Frye (1989)
  31. Reid AH, Tsai MM, Venzon DJ, Wright CF, Lack EE, O'Leary TJ: MDM2 amplification, P53 mutation, and accumulation of the P53 gene product in malignant fibrous histiocytoma. Diagn Mol Pathol 5: 65-73, 1996 (10.1097/00019606-199603000-00010) / Diagn Mol Pathol by AH Reid (1996)
  32. Seki A, Kodama J, Miyagi Y, Kamimura S, Yoshinouchi M, Kudo T: Amplification of the mdm-2 gene and p53 abnormalities in uterine sarcomas. Int J Cancer 73: 33-37, 1997 (10.1002/(SICI)1097-0215(19970926)73:1<33::AID-IJC6>3.0.CO;2-2) / Int J Cancer by A Seki (1997)
  33. Raff T, van der Giet M, Endemann D, Wiederholt T, Paul M: Design and testing of beta-act in primers for RT-PCR that do not co-amplify processed pseudogenes. Biotechniques 23: 456-460, 1997 (10.2144/97233st02) / Biotechniques by T Raff (1997)
  34. Done SJ, Arneson ACR, Özçelik H, Redston M, Andrulis IL: p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias. Cancer Res 58: 785-789, 1998 / Cancer Res by SJ Done (1998)
  35. Soussi T, de Fromentel CC, May P: Structural aspects of the p53 protein in relation to gene evolution. Oncogene 5: 945-952, 1990 / Oncogene by T Soussi (1990)
  36. Carbone D, Chiba T, Mitsudomi T: Polymorphism at codon 213 within the p53 gene. Oncogene 6: 1691-1692, 1991 / Oncogene by D Carbone (1991)
  37. Momand J, Jung D, Wilczynski S, Niland J: The MDM2 gene amplification database. Nucleic Acids Res 26: 3453-3459, 1998 (10.1093/nar/26.15.3453) / Nucleic Acids Res by J Momand (1998)
  38. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 80-83, 1992 (10.1038/358080a0) / Nature by JD Oliner (1992)
  39. Sheikh MS, Shao Z-M, Hussain A, Fontana JA: The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Res 53: 3226-3228, 1993 / Cancer Res by MS Sheikh (1993)
  40. Gazzeri S, Valle VD, Chaussade L, Brambilla C, Larsen CJ, Brambilla E: The human p19ARF prote in encoded by the b transcript of the p16 INK4a gene is frequently lost in small cell lung cancer. Cancer Res 58: 3926-3931, 1998 / Cancer Res by S Gazzeri (1998)
  41. Fitzgerald MG, Harkin DP, Silva-Arrieta S, MacDonald DJ, Lucchina LC, Unsal H, O'Neill E, Koh J, Finkelstein DM, Isselbacher KJ, Sober AJ, Haber DA: Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci USA 93: 8541-8545, 1996 (10.1073/pnas.93.16.8541) / Proc Natl Acad Sci USA by MG Fitzgerald (1996)
  42. Van Zee KJ, Calvano JE, Bisogna M, Borgen PI: INK4a exon 1bβ is wildtype in MCF-7. Proc AACR 39: 441, 1998 / Proc AACR by KJ Van Zee (1998)
  43. Della Valle V, Duro D, Bernard O, Larsen CJ: The human protein p19ARF is not detected in hemopoietic human cell lines that abundantly express the alternative b transcript of the p16INK4a/MTS1 gene. Oncogene 15: 2475-2481, 1997 (10.1038/sj.onc.1201417) / Oncogene by V Della Valle (1997)
Dates
Type When
Created 22 years, 8 months ago (Dec. 22, 2002, 10:31 p.m.)
Deposited 2 months, 1 week ago (June 21, 2025, 12:25 a.m.)
Indexed 2 months, 1 week ago (June 22, 2025, 12:01 a.m.)
Issued 24 years, 6 months ago (Feb. 1, 2001)
Published 24 years, 6 months ago (Feb. 1, 2001)
Published Print 24 years, 6 months ago (Feb. 1, 2001)
Funders 0

None

@article{Ho_2001, title={Genetic Alterations of the p14ARF-hdm2-p53 Regulatory Pathway in Breast Carcinoma}, volume={65}, ISSN={1573-7217}, url={http://dx.doi.org/10.1023/a:1010686518990}, DOI={10.1023/a:1010686518990}, number={3}, journal={Breast Cancer Research and Treatment}, publisher={Springer Science and Business Media LLC}, author={Ho, Gay Hui and Calvano, Jacqueline E. and Bisogna, Maria and Abouezzi, Ziad and Borgen, Patrick I. and Cordón-Cardó, Carlos and Zee, Kimberly J. Van}, year={2001}, month=feb, pages={225–232} }